Reduced COVID-19 severity elicited by weight loss from a medically supervised ketogenic diet in a geographically diverse ambulatory population with type 2 diabetes and obesity.
Brittanie M Volk, Caroline G P Roberts, Michelle VanTieghem, M Patricia George, Rebecca N Adams, Shaminie J Athinarayanan, Amy L McKenzie
{"title":"Reduced COVID-19 severity elicited by weight loss from a medically supervised ketogenic diet in a geographically diverse ambulatory population with type 2 diabetes and obesity.","authors":"Brittanie M Volk, Caroline G P Roberts, Michelle VanTieghem, M Patricia George, Rebecca N Adams, Shaminie J Athinarayanan, Amy L McKenzie","doi":"10.1136/bmjnph-2022-000444","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate factors associated with COVID-19 severity in ambulatory individuals with type 2 diabetes mellitus (T2DM) and obesity treated with a medically supervised ketogenic diet (MSKD).</p><p><strong>Research design and methods: </strong>In this real-world, retrospective, exploratory analysis, multivariate modelling was used to assess clinical factors associated with hospitalisation for COVID-19 in a geographically diverse outpatient population with T2DM treated virtually.</p><p><strong>Results: </strong>Leading up to COVID-19 onset, non-hospitalised patients had higher average ketones (0.64 vs 0.52 mmol/L; p=0.016) and greater weight loss (6.8% vs 4.2%; p=0.009) compared with those hospitalised. Greater weight loss was significantly associated with lower likelihood of hospitalisation (adjusted OR=0.91, p=0.005), controlling for enrolment demographics and medical characteristics.</p><p><strong>Conclusions: </strong>Therapies such as MSKD, which elicit rapid, significant weight loss, may favourably impact COVID-19 hospitalisation rate and severity in individuals with T2DM and obesity.</p>","PeriodicalId":72435,"journal":{"name":"","volume":"5 2","pages":"154-158"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ed/71/bmjnph-2022-000444.PMC9813610.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjnph-2022-000444","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Objective: To investigate factors associated with COVID-19 severity in ambulatory individuals with type 2 diabetes mellitus (T2DM) and obesity treated with a medically supervised ketogenic diet (MSKD).
Research design and methods: In this real-world, retrospective, exploratory analysis, multivariate modelling was used to assess clinical factors associated with hospitalisation for COVID-19 in a geographically diverse outpatient population with T2DM treated virtually.
Results: Leading up to COVID-19 onset, non-hospitalised patients had higher average ketones (0.64 vs 0.52 mmol/L; p=0.016) and greater weight loss (6.8% vs 4.2%; p=0.009) compared with those hospitalised. Greater weight loss was significantly associated with lower likelihood of hospitalisation (adjusted OR=0.91, p=0.005), controlling for enrolment demographics and medical characteristics.
Conclusions: Therapies such as MSKD, which elicit rapid, significant weight loss, may favourably impact COVID-19 hospitalisation rate and severity in individuals with T2DM and obesity.
目的:探讨采用医学监督生酮饮食(MSKD)治疗的2型糖尿病(T2DM)和肥胖患者中与COVID-19严重程度相关的因素。研究设计和方法:在这一现实世界中，回顾性、探索性分析，采用多变量模型来评估地理位置不同的T2DM门诊人群中与COVID-19住院相关的临床因素。结果:在COVID-19发病前，非住院患者的平均酮含量较高(0.64 vs 0.52 mmol/L;P =0.016)和更大的体重减轻(6.8% vs 4.2%;P =0.009)。体重减轻越多，住院的可能性越低(调整OR=0.91, p=0.005)，控制了入组人口统计学和医学特征。结论:MSKD等治疗可导致快速、显著的体重减轻，可能有利于影响T2DM和肥胖患者的COVID-19住院率和严重程度。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
